期刊
PHARMACEUTICALS
卷 16, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/ph16091197
关键词
LDL; lipoprotein a; platelet activation; thrombus
Atherosclerosis as the main cause of cardiovascular disease can be effectively prevented and treated by PCSK9 inhibitors, which not only lower LDL cholesterol but also inhibit atherosclerosis progression through LDL-independent mechanisms.
Atherosclerosis is the primary process that underlies cardiovascular disease. The connection between LDL cholesterol and the formation of atherosclerotic plaques is established by solid evidence. PCSK9 inhibitors have proven to be a valuable and practical resource for lowering the LDL cholesterol of many patients in recent years. Their inhibitory effect on atherosclerosis progression seems to be driven not just by lipid metabolism modification but also by LDL-independent mechanisms. We review the effect of PCSK9 inhibitors on various mechanisms involving platelet activation, inflammation, endothelial dysfunction, and the resultant clot formation. The main effectors of PCSK9 activation of platelets are CD36 receptors, lipoprotein(a), oxidised LDL particles, tissue factor, and factor VIII. Many more molecules are under investigation, and this area of research is growing rapidly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据